Hydrolyzed infant formula and early β-cell autoimmunity: a randomized clinical trial

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Hydrolyzed infant formula and early β-cell autoimmunity : a randomized clinical trial. / Knip, Mikael; Åkerblom, Hans K; Becker, Dorothy; Dosch, Hans-Michael; Dupre, John; Fraser, William; Howard, Neville; Ilonen, Jorma; Krischer, Jeffrey P; Kordonouri, Olga; Lawson, Margaret L; Palmer, Jerry P; Savilahti, Erkki; Vaarala, Outi; Virtanen, Suvi M; TRIGR Study Group ; Mandrup-Poulsen, Thomas.

In: JAMA : the journal of the American Medical Association, Vol. 311, No. 22, 11.06.2014, p. 2279-87.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Knip, M, Åkerblom, HK, Becker, D, Dosch, H-M, Dupre, J, Fraser, W, Howard, N, Ilonen, J, Krischer, JP, Kordonouri, O, Lawson, ML, Palmer, JP, Savilahti, E, Vaarala, O, Virtanen, SM, TRIGR Study Group & Mandrup-Poulsen, T 2014, 'Hydrolyzed infant formula and early β-cell autoimmunity: a randomized clinical trial', JAMA : the journal of the American Medical Association, vol. 311, no. 22, pp. 2279-87. https://doi.org/10.1001/jama.2014.5610

APA

Knip, M., Åkerblom, H. K., Becker, D., Dosch, H-M., Dupre, J., Fraser, W., Howard, N., Ilonen, J., Krischer, J. P., Kordonouri, O., Lawson, M. L., Palmer, J. P., Savilahti, E., Vaarala, O., Virtanen, S. M., TRIGR Study Group, & Mandrup-Poulsen, T. (2014). Hydrolyzed infant formula and early β-cell autoimmunity: a randomized clinical trial. JAMA : the journal of the American Medical Association, 311(22), 2279-87. https://doi.org/10.1001/jama.2014.5610

Vancouver

Knip M, Åkerblom HK, Becker D, Dosch H-M, Dupre J, Fraser W et al. Hydrolyzed infant formula and early β-cell autoimmunity: a randomized clinical trial. JAMA : the journal of the American Medical Association. 2014 Jun 11;311(22):2279-87. https://doi.org/10.1001/jama.2014.5610

Author

Knip, Mikael ; Åkerblom, Hans K ; Becker, Dorothy ; Dosch, Hans-Michael ; Dupre, John ; Fraser, William ; Howard, Neville ; Ilonen, Jorma ; Krischer, Jeffrey P ; Kordonouri, Olga ; Lawson, Margaret L ; Palmer, Jerry P ; Savilahti, Erkki ; Vaarala, Outi ; Virtanen, Suvi M ; TRIGR Study Group ; Mandrup-Poulsen, Thomas. / Hydrolyzed infant formula and early β-cell autoimmunity : a randomized clinical trial. In: JAMA : the journal of the American Medical Association. 2014 ; Vol. 311, No. 22. pp. 2279-87.

Bibtex

@article{37d81272fd324525a87b904fc52da8cd,
title = "Hydrolyzed infant formula and early β-cell autoimmunity: a randomized clinical trial",
abstract = "IMPORTANCE: The disease process leading to clinical type 1 diabetes often starts during the first years of life. Early exposure to complex dietary proteins may increase the risk of β-cell autoimmunity in children at genetic risk for type 1 diabetes. Extensively hydrolyzed formulas do not contain intact proteins.OBJECTIVE: To test the hypothesis that weaning to an extensively hydrolyzed formula decreases the cumulative incidence of diabetes-associated autoantibodies in young children.DESIGN, SETTING, AND PARTICIPANTS: A double-blind randomized clinical trial of 2159 infants with HLA-conferred disease susceptibility and a first-degree relative with type 1 diabetes recruited from May 2002 to January 2007 in 78 study centers in 15 countries; 1078 were randomized to be weaned to the extensively hydrolyzed casein formula and 1081 were randomized to be weaned to a conventional cows' milk-based formula. The participants were observed to April 16, 2013.INTERVENTIONS: The participants received either a casein hydrolysate or a conventional cows' milk formula supplemented with 20% of the casein hydrolysate.MAIN OUTCOMES: AND MEASURES: Primary outcome was positivity for at least 2 diabetes-associated autoantibodies out of 4 analyzed. Autoantibodies to insulin, glutamic acid decarboxylase, and the insulinoma-associated-2 (IA-2) molecule were analyzed using radiobinding assays and islet cell antibodies with immunofluorescence during a median observation period of 7.0 years (mean, 6.3 years).RESULTS: The absolute risk of positivity for 2 or more islet autoantibodies was 13.4% among those randomized to the casein hydrolysate formula (n = 139) vs 11.4% among those randomized to the conventional formula (n = 117). The unadjusted hazard ratio for positivity for 2 or more autoantibodies among those randomized to be weaned to the casein hydrolysate was 1.21 (95% CI, 0.94-1.54), compared with those randomized to the conventional formula, while the hazard ratio adjusted for HLA risk, duration of breastfeeding, vitamin D use, study formula duration and consumption, and region was 1.23 (95% CI, 0.96-1.58). There were no clinically significant differences in the rate of reported adverse events between the 2 groups.CONCLUSIONS AND RELEVANCE: Among infants at risk for type 1 diabetes, the use of a hydrolyzed formula, when compared with a conventional formula, did not reduce the incidence of diabetes-associated autoantibodies after 7 years. These findings do not support a benefit from hydrolyzed formula. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00179777.",
author = "Mikael Knip and {\AA}kerblom, {Hans K} and Dorothy Becker and Hans-Michael Dosch and John Dupre and William Fraser and Neville Howard and Jorma Ilonen and Krischer, {Jeffrey P} and Olga Kordonouri and Lawson, {Margaret L} and Palmer, {Jerry P} and Erkki Savilahti and Outi Vaarala and Virtanen, {Suvi M} and {TRIGR Study Group} and Thomas Mandrup-Poulsen",
year = "2014",
month = jun,
day = "11",
doi = "10.1001/jama.2014.5610",
language = "English",
volume = "311",
pages = "2279--87",
journal = "JAMA - Journal of the American Medical Association",
issn = "0098-7484",
publisher = "American Medical Association",
number = "22",

}

RIS

TY - JOUR

T1 - Hydrolyzed infant formula and early β-cell autoimmunity

T2 - a randomized clinical trial

AU - Knip, Mikael

AU - Åkerblom, Hans K

AU - Becker, Dorothy

AU - Dosch, Hans-Michael

AU - Dupre, John

AU - Fraser, William

AU - Howard, Neville

AU - Ilonen, Jorma

AU - Krischer, Jeffrey P

AU - Kordonouri, Olga

AU - Lawson, Margaret L

AU - Palmer, Jerry P

AU - Savilahti, Erkki

AU - Vaarala, Outi

AU - Virtanen, Suvi M

AU - TRIGR Study Group

AU - Mandrup-Poulsen, Thomas

PY - 2014/6/11

Y1 - 2014/6/11

N2 - IMPORTANCE: The disease process leading to clinical type 1 diabetes often starts during the first years of life. Early exposure to complex dietary proteins may increase the risk of β-cell autoimmunity in children at genetic risk for type 1 diabetes. Extensively hydrolyzed formulas do not contain intact proteins.OBJECTIVE: To test the hypothesis that weaning to an extensively hydrolyzed formula decreases the cumulative incidence of diabetes-associated autoantibodies in young children.DESIGN, SETTING, AND PARTICIPANTS: A double-blind randomized clinical trial of 2159 infants with HLA-conferred disease susceptibility and a first-degree relative with type 1 diabetes recruited from May 2002 to January 2007 in 78 study centers in 15 countries; 1078 were randomized to be weaned to the extensively hydrolyzed casein formula and 1081 were randomized to be weaned to a conventional cows' milk-based formula. The participants were observed to April 16, 2013.INTERVENTIONS: The participants received either a casein hydrolysate or a conventional cows' milk formula supplemented with 20% of the casein hydrolysate.MAIN OUTCOMES: AND MEASURES: Primary outcome was positivity for at least 2 diabetes-associated autoantibodies out of 4 analyzed. Autoantibodies to insulin, glutamic acid decarboxylase, and the insulinoma-associated-2 (IA-2) molecule were analyzed using radiobinding assays and islet cell antibodies with immunofluorescence during a median observation period of 7.0 years (mean, 6.3 years).RESULTS: The absolute risk of positivity for 2 or more islet autoantibodies was 13.4% among those randomized to the casein hydrolysate formula (n = 139) vs 11.4% among those randomized to the conventional formula (n = 117). The unadjusted hazard ratio for positivity for 2 or more autoantibodies among those randomized to be weaned to the casein hydrolysate was 1.21 (95% CI, 0.94-1.54), compared with those randomized to the conventional formula, while the hazard ratio adjusted for HLA risk, duration of breastfeeding, vitamin D use, study formula duration and consumption, and region was 1.23 (95% CI, 0.96-1.58). There were no clinically significant differences in the rate of reported adverse events between the 2 groups.CONCLUSIONS AND RELEVANCE: Among infants at risk for type 1 diabetes, the use of a hydrolyzed formula, when compared with a conventional formula, did not reduce the incidence of diabetes-associated autoantibodies after 7 years. These findings do not support a benefit from hydrolyzed formula. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00179777.

AB - IMPORTANCE: The disease process leading to clinical type 1 diabetes often starts during the first years of life. Early exposure to complex dietary proteins may increase the risk of β-cell autoimmunity in children at genetic risk for type 1 diabetes. Extensively hydrolyzed formulas do not contain intact proteins.OBJECTIVE: To test the hypothesis that weaning to an extensively hydrolyzed formula decreases the cumulative incidence of diabetes-associated autoantibodies in young children.DESIGN, SETTING, AND PARTICIPANTS: A double-blind randomized clinical trial of 2159 infants with HLA-conferred disease susceptibility and a first-degree relative with type 1 diabetes recruited from May 2002 to January 2007 in 78 study centers in 15 countries; 1078 were randomized to be weaned to the extensively hydrolyzed casein formula and 1081 were randomized to be weaned to a conventional cows' milk-based formula. The participants were observed to April 16, 2013.INTERVENTIONS: The participants received either a casein hydrolysate or a conventional cows' milk formula supplemented with 20% of the casein hydrolysate.MAIN OUTCOMES: AND MEASURES: Primary outcome was positivity for at least 2 diabetes-associated autoantibodies out of 4 analyzed. Autoantibodies to insulin, glutamic acid decarboxylase, and the insulinoma-associated-2 (IA-2) molecule were analyzed using radiobinding assays and islet cell antibodies with immunofluorescence during a median observation period of 7.0 years (mean, 6.3 years).RESULTS: The absolute risk of positivity for 2 or more islet autoantibodies was 13.4% among those randomized to the casein hydrolysate formula (n = 139) vs 11.4% among those randomized to the conventional formula (n = 117). The unadjusted hazard ratio for positivity for 2 or more autoantibodies among those randomized to be weaned to the casein hydrolysate was 1.21 (95% CI, 0.94-1.54), compared with those randomized to the conventional formula, while the hazard ratio adjusted for HLA risk, duration of breastfeeding, vitamin D use, study formula duration and consumption, and region was 1.23 (95% CI, 0.96-1.58). There were no clinically significant differences in the rate of reported adverse events between the 2 groups.CONCLUSIONS AND RELEVANCE: Among infants at risk for type 1 diabetes, the use of a hydrolyzed formula, when compared with a conventional formula, did not reduce the incidence of diabetes-associated autoantibodies after 7 years. These findings do not support a benefit from hydrolyzed formula. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00179777.

U2 - 10.1001/jama.2014.5610

DO - 10.1001/jama.2014.5610

M3 - Journal article

C2 - 24915259

VL - 311

SP - 2279

EP - 2287

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0098-7484

IS - 22

ER -

ID: 114432392